A drug derived from Norwegian seaweed may help increase the life expectancy of people with cystic fibrosis, which currently averages about 40 years. The Norwegian company AlgiPharma presented OligoG at the 37th European Cystic Fibrosis Conference in Gothenburg, Sweden recently, revealing…
News
Greek researchers at Athens University Medical School and Aghia Sophia Children’s Hospital uncovered psychosocial vulnerability in children and adolescents with cystic fibrosis. A study of 36 cystic fibrosis patients, aged 8-18 years, and 31 healthy, age-matched control participants revealed that cystic fibrosis patients have a greater difficulty establishing friendships and…
Bernstein Research analyst Geoff Porges advised investors about the probability of failure of the Vertex Pharmaceuticals’ experimental cystic fibrosis (CF) therapy, as he returned from the European Cystic Fibrosis Society conference in Sweden. Although test results of the combination of Kalydeco and VX-809 – Traffic and Transport has been eagerly…
Clinical-stage biotech company Galapagos, which is based in Belgium, has announced positive results of a Phase II clinical trial for two oral drugs designed to treat the main mutations in cystic fibrosis (CF) patients, including F508del and G551D. AbbVie has been working in collaboration with Galapagos in order to further the development…
Cambridge, Massachusetts-based Vertex Pharmaceuticals Incorporated announced Monday that it has signed a letter of intent with the pan-Canadian Pricing Alliance (pCPA) to enable public reimbursement of Kalydeco (ivacaftor) drug therapy for treatment of eligible Canadians ages 6 and older with cystic fibrosis (CF) who have the G551D gene…
Last Wednesday, the 37th European Cystic Fibrosis Conference gathered leading CF caregivers and researchers in Gothenburg, Sweden. The four-day program included seminars, round table talks, Meet the Expert sessions, and a physiotherapy short course, in order to facilitate acquisition and distribution of new knowledge and research in…
A recent study published in the Iranian Journal of Pediatrics suggests that taking probiotics supplements can help improve quality of life for patients with cystic fibrosis (CF). Persons with CF (and many other disease conditions) frequently suffer from imbalanced intestinal microbiota ecosystems and suffer consequent dysregulated immune functionalities exacerbated…
At the 37th European Cystic Fibrosis Society Conference, held June 11-14 in Sweden, representatives from Vertex Pharmaceuticals Inc. presented data from multiple clinical trials evaluating Kalydeco (ivacaftor) in patients with cystic fibrosis due to various mutations. “Not only does KALYDECO lead to significant initial improvements,…
Young people who suffer from physical disabilities or illnesses, such as cystic fibrosis, don’t always receive all of the necessary care and support they need to make a transition to care services. These are the conclusions of a study from the English Care and Quality Commission that reviewed…
For the 27th year, Cystic Fibrosis Research Inc. will hold a national conference to raise awareness of the disease and advocate for continued research and drug development. “Changing the Faces of Cystic Fibrosis: Inspiring Hope” will take place in San Francisco from August 1st through the 3rd, with several presentations designed…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.